We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Effects of Prostacyclin Infusion on Cerebral Vessels and Metabolism in Patients With Subarachnoid Haemorrhage

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01447095
Recruitment Status : Completed
First Posted : October 5, 2011
Last Update Posted : July 21, 2014
Information provided by (Responsible Party):
Rune Rasmussen, Rigshospitalet, Denmark

Brief Summary:
The purpose of this study is to determine whether prostacyclin is effective in prevention of cerebral vasospasm in patients with subarachnoidal hemorrhage (SAH).

Condition or disease Intervention/treatment Phase
Subarachnoid Hemorrhage Drug: Prostacyclin 1 ng/kg/min Drug: Prostacyclin 2 ng/kg/min Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Effect of Prostacyclin Infusion on Cerebral Vessels, Cerebral Bloodflow and Cerebral Metabolism in Patients With Subarachnoid Haemorrhage
Study Start Date : October 2011
Actual Primary Completion Date : June 2014
Actual Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bleeding

Arm Intervention/treatment
Active Comparator: Low dose prostacyclin Drug: Prostacyclin 1 ng/kg/min
Continuous i.v. infusion of epoprostenol 1 ng/kg/min day 5-10 after SAH
Other Name: Flolan

Active Comparator: High dose prostacyclin Drug: Prostacyclin 2 ng/kg/min
Continuous i.v. infusion of epoprostenol 2 ng/kg/min day 5-10 after SAH
Other Name: Flolan

Placebo Comparator: Placebo Drug: Placebo
Continuous i.v. infusion with placebo day 5-10 after SAH

Primary Outcome Measures :
  1. Radiographic vasospasm measured by CT perfusion [ Time Frame: Day 8 (+/- 1 day) after aneurysm treatment ]
    Changes in regional cerebral blood flow from baseline in the arterial territories of the anterior cerebral artery, medial cerebral artery and the posterior cerebral artery

Secondary Outcome Measures :
  1. Cerebral metabolism measured by microdialysis [ Time Frame: every 2. hour day 3-10 after aneurysm treatment ]
    Cerebral metabolism measured by microdialysis. Lactate, pyruvate, glucose, glutamate and glycerol are measured.

  2. Glasgow outcome scale (GOS) at 3 months [ Time Frame: 3 months efter SAH ]
    Glasgow outcome scale (GOS) at 3 months obtained by telephone interview.

  3. Clinical vasospasm [ Time Frame: day 5-10 after SAH ]
    Clinical vasospasm defined as delayed neurological deficits (DIND).

  4. Brain tissue oxygen (PtiO2) [ Time Frame: continuous measurement day 3-10 after SAH ]
    Brain tissue oxygen (PtiO2) measured by Licox catheter.

  5. Mean arterial pressure (MAP) [ Time Frame: Continuous day 1-10 after SAH ]
    Mean arterial pressure (MAP) measured by arterial catheter.

  6. Radiographic vasospasm measured by CT angiography [ Time Frame: Measured day 8 +/- 1 day ]
    Qualitative assessment (none, mild/moderate, severe) of vasospasm.

  7. Level of brain damage biomarker [ Time Frame: daily day 4-11 after SAH ]
    Serum levels of S100b in peripheral blood

Other Outcome Measures:
  1. Neuropeptide Y [ Time Frame: May 2014 ]
    Neuropeptide Y will be measured in all patients Day 2-11. The concentration will be related to CBF, angiographic vasospasm and clinical outcome for all patients. The results will be reported in a separate puplication.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • SAH verified by CT
  • Aneurysm identified and treated
  • Fisher grade 3 + 4
  • WFNS grade 1-4 (World Federation of Neurosurgical Societies )

Exclusion Criteria:

  • Pregnancy/lactation
  • Heard failure
  • Kidney failure
  • Liver failure
  • Hemorrhagic diathesis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01447095

Layout table for location information
Rigshospitalet, dep. of neurosurgery
Copenhagen, Denmark, 2200
Sponsors and Collaborators
Rune Rasmussen
Layout table for investigator information
Principal Investigator: Rune Rasmussen, MD Rigshospitalet, Denmark
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Rune Rasmussen, MD, Sponsor-Investigator, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT01447095    
Other Study ID Numbers: 2011-002798-50
First Posted: October 5, 2011    Key Record Dates
Last Update Posted: July 21, 2014
Last Verified: July 2014
Keywords provided by Rune Rasmussen, Rigshospitalet, Denmark:
Subarachnoid hemorrhage
Additional relevant MeSH terms:
Layout table for MeSH terms
Subarachnoid Hemorrhage
Pathologic Processes
Intracranial Hemorrhages
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents
Platelet Aggregation Inhibitors
Vasodilator Agents